Newman Dignan & Sheerar Inc. Sells 2,027 Shares of Pfizer Inc. (NYSE:PFE)

Newman Dignan & Sheerar Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 6.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 30,625 shares of the biopharmaceutical company’s stock after selling 2,027 shares during the period. Newman Dignan & Sheerar Inc.’s holdings in Pfizer were worth $1,110,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Kinloch Capital LLC bought a new position in Pfizer during the fourth quarter worth about $25,000. Alpha DNA Investment Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Penbrook Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $27,000. Orion Capital Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $29,000. Finally, Merrion Investment Management Co LLC acquired a new stake in Pfizer during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 67.36% of the company’s stock.

Shares of PFE traded up $0.29 during trading hours on Monday, hitting $40.31. The company’s stock had a trading volume of 124,841 shares, compared to its average volume of 31,854,996. The company has a market cap of $224.83 billion, a price-to-earnings ratio of 25.82, a PEG ratio of 2.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.40 and a quick ratio of 1.13. The business has a 50 day simple moving average of $37.93 and a two-hundred day simple moving average of $36.89. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 4th. The biopharmaceutical company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.78 by $0.15. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The company had revenue of $14.58 billion during the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the previous year, the company earned $0.80 earnings per share. Pfizer’s revenue for the quarter was up 44.6% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.89 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be issued a $0.39 dividend. The ex-dividend date is Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.87%. Pfizer’s payout ratio is 52.88%.

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $45.11 price target on shares of Pfizer in a research report on Thursday. Mizuho reissued a “neutral” rating and set a $42.00 price target on shares of Pfizer in a research report on Wednesday, May 12th. SVB Leerink boosted their price target on shares of Pfizer from $39.00 to $43.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 11th. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b-” rating in a research note on Monday, May 3rd. Finally, DZ Bank restated a “buy” rating and set a $41.00 price objective on shares of Pfizer in a research note on Wednesday, February 3rd. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average target price of $39.74.

In related news, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction on Wednesday, May 5th. The shares were sold at an average price of $40.82, for a total transaction of $102,050.00. Following the completion of the sale, the senior vice president now directly owns 13,748 shares in the company, valued at approximately $561,193.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.08% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Read More: High-Yield Dividend Stocks

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.